

# **Appendix 1 (as supplied by the authors):** Forest plots for various analyses of benefits, harms and sensitivity analyses

Forest plot (standardized mean difference) of percentage change from baseline in weekly incontinence episodes



### Forest plot (standardized mean difference) of sensitivity analysis of percentage change from baseline in weekly incontinence episodes



### Forest plot (standardized mean difference) of numerical change from baseline in weekly incontinence episodes

	Dulox	Duloxetine 80mg			Placebo			Std. Mean Difference	Std. Mean Difference	
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Fixed, 95% CI	IV, Fixed, 95% CI	
SAAW	-4.12	10.36	119	-2.48	7.61	128	14.3%	-0.18 [-0.43, 0.07]		
SBAT	-7.02	12.39	212	-3.68	10.16	242	26.1%	-0.30 [-0.48, -0.11]		
SBAV	-8.4	11.39	286	-4.22	13.03	322	34.8%	-0.34 [-0.50, -0.18]		
SBAX	-8.49	12.45	200	-6.79	10.71	229	24.8%	-0.15 [0.34, 0.04]		
Total (95% CI)			817			921	100.0%	-0.26 [-0.35, -0.16]	•	
Heterogeneity: Chi <sup>2</sup> = 2.84, df = 3 (P = 0.42); l <sup>2</sup> = 0%								and the second se		
Test for overall effect: Z = 5.34 (P < 0.00001)									-1 -0.5 0 0.5 1 Favours duloxetine 80mg Favours placebo	


Appendix to: Maund E, Schow Guski L, Gøtzsche PC. Considering benefits and harms of duloxetine for treatment of stress urinary incontinence: a meta-analysis of clinical study reports. *CMAJ* 2016. DOI:10.1503/cmaj.151104.

> Copyright © 2017 The Author(s) or their employer(s). To receive this resource in an accessible format, please contact us at cmajgroup@cmaj.ca.

Forest plot (standardized mean difference) of change in Incontinence Quality of Life total score

	Dulox	Duloxetine 80mg			Placebo			Std. Mean Difference	Std. Mean Difference	
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Fixed, 95% CI	IV, Fixed, 95% CI	
SAAW	9.3	11.48	130	5.84	9.99	132	14.0%	0.32 [0.08, 0.56]		
SBAT	5.54	13.97	240	4.07	12.5	245	26.2%	0.11 [-0.07, 0.29]		
SBAV	11.01	14.79	333	6.8	13.38	332	35.6%	0.30 [0.15, 0.45]		
SBAX	10.34	15.99	220	6.42	17.03	229	24.1%	0.24 [0.05, 0.42]		
Total (95% CI)			923			938	100.0%	0.24 [0.15, 0.33]	•	
Heterogeneity: Chi <sup>2</sup> =	: 3.00, df	= 3 (P =	0.39);	<sup>2</sup> = 0%						
Test for overall effect									-1 -0.5 0 0.5 1 Favours placebo Favours duloxetine 80mg	

# Forest plot (risk ratio) of Patient Global Impression of Improvement (PGI-I) responses of "much better or very much better".



### Forest plot (risk ratio) of sensitivity analysis 1 of PGI-I responses of "much better or very much better".

	Duloxetine 80mg Events Total 57 130		Placebo			<b>Risk Ratio</b>	Risk Ratio	
Study or Subgroup			Events	Total	Weight	M-H, Fixed, 95% CI		M-H, Fixed, 95% CI
SAAW			36	132	18.2%	1.61 [1.14, 2.26]		
SBAT	85	240	69	243	34.9%	1.25 [0.96, 1.62]		
SBAV	128	334	75	333	0.0%	1.70 [1.34, 2.17]		
SBAX	97	220	94	229	46.9%	1.07 [0.87, 1.33]		
Total (95% CI)		590		604	100.0%	1.23 [1.06, 1.43]		◆
Total events	239		199					
Heterogeneity: Chi <sup>2</sup> =	: 3.93, df = 2 (	P = 0.14	; I= 499	6			+	
Test for overall effect		S	1. 10 CAN				0.2	0.5 1 2 5 Favours placebo Favours duloxetine 80mg

Forest plot (risk ratio) of sensitivity analysis 2 of PGI-I responses of "much better or very much better".

	Duloxetine 80mg		Placebo		Risk Ratio		Risk Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% CI	M-H, Fixed, 95% Cl
SAAW	57	130	36	132	19.9%	1.61 [1.14, 2.26]	]
SBAT	85	240	69	243	38.2%	1.25 [0.96, 1.62]	1 +=-
SBAV	128	334	75	333	41.9%	1.70 [1.34, 2.17]	1 –
SBAX	97	220	94	229	0.0%	1.07 [0.87, 1.33]	1
Total (95% CI)		704		708	100.0%	1.51 [1.29, 1.77]	•
Total events	270		180				
Heterogeneity: Chi <sup>2</sup> =	3.10, df = 2 (	P = 0.21)	; I <sup>2</sup> = 369	6			
Test for overall effect	Z= 5.13 (P <	0.00001	)				0.2 0.5 1 2 5 Favours placebo Favours duloxetine 80mg

# Forest plot (risk difference) of sensitivity analysis 2 of PGI-I responses of "much better or very much better".

	Duloxetine	Place	bo	Risk Difference			Risk Difference		
Study or Subgroup	Events Total		Events Tota		Weight	M-H, Fixed, 95% CI		M-H, Fixed, 95% CI	
SAAW	57	130	36	132	18.6%	0.17 [0.05, 0.28]			
SBAT	85	240	69	243	34.2%	0.07 [-0.01, 0.15]			
SBAV	128	334	75	333	47.2%	0.16 [0.09, 0.23]			
SBAX	97	220	94	229	0.0%	0.03 [-0.06, 0.12]			
Total (95% CI)		704		708	100.0%	0.13 [0.08, 0.18]		•	
Total events	270		180						
Heterogeneity Chi <sup>2</sup> =	3.01, df = 2 (F	= 0.22	; I <sup>2</sup> = 34%	5			H		-
Test for overall effect							-1	-0.5 0 0.5 Favours placebo Favours duloxetine 80n	ng

### Forest plot (risk difference) of experiencing at least one treatment emergent adverse event

	Duloxetine 80mg Events Total		Placebo			<b>Risk Difference</b>	Risk Difference
Study or Subgroup			Events	vents Total	Weight	M-H, Fixed, 95% CI	M-H, Fixed, 95% CI
SAAW	101	140	84	138	14.5%	0.11 [0.00, 0.22]	• • • • • • • • • • • • • • • • • • •
SBAT	198	247	158	247	25.8%	0.16 [0.08, 0.24]	
SBAV	255	344	169	339	35.7%	0.24 [0.17, 0.31]	
SBAX	173	227	137	231	23.9%	0.17 [0.08, 0.25]	
Total (95% CI)		958		955	100.0%	0.19 [0.14, 0.23]	•
Total events	727		548				
Heterogeneity Chi <sup>2</sup> =	4.70, df = 3 (f	= 0.19	; I <sup>2</sup> = 369	6			
Test for overall effect: Z = 8.81 (P < 0.00001)							-0.5 -0.25 0 0.25 0.5 Favours duloxetine 80mg Favours placebo

Forest plot	(risk rati	o) of	sensitivity	analysis	of	experiencing	at least	one
treatment em	ergent adv	erse	event					

	Duloxetine 80mg		Placebo			Risk Ratio	Risk Ratio
Study or Subgroup	Events Total		Events	Total	Weight	M-H, Fixed, 95% CI	M-H, Fixed, 95% CI
SAAW	101	140	84	138	22.4%	1.19 [1.00, 1.40]	
SBAT	198	247	158	247	41.8%	1.25 [1.12, 1.40]	
SBAV	255	344	169	339	0.0%	1.49 [1.31, 1.68]	
SBAX	173	227	137	231	35.9%	1.29 [1.13, 1.46]	
Total (95% CI)		614		616	100.0%	1.25 [1.16, 1.35]	•
Total events	472		379				- 1894 ().
Heterogeneity: Chi <sup>2</sup> =	0.56, df = 2 (	P = 0.76	; I <sup>2</sup> = 0%				0.5 0.7 1 1.5
est for overall effect: Z = 5.75 (P < 0.00001)							Favours duloxetine 80mg Favours placebo


# Forest plot (risk difference) of sensitivity analysis of experiencing at least one treatment emergent adverse event

	Duloxetine	Duloxetine 80mg		Placebo		<b>Risk Difference</b>	Risk Difference
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% CI	M-H, Fixed, 95% Cl
SAAW	101	140	84	138	22.6%	0.11 [0.00, 0.22]	
SBAT	198	247	158	247	40.2%	0.16 [0.08, 0.24]	
SBAV	255	344	169	339	0.0%	1.49 [1.31, 1.68]	
SBAX	173	227	137	231	37.2%	0.17 [0.08, 0.25]	_ <b>_</b> _
Total (95% CI)		614		616	100.0%	0.15 [0.10, 0.20]	•
Total events	472		379				
Heterogeneity: Chi <sup>2</sup> =	0.70, df= 2 (	P = 0.70	; I= 0%			2	
est for overall effect: Z = 5.92 (P < 0.00001)							-0.5 -0.25 0 0.25 0.5 Favours duloxetine 80mg Favours placebo

#### Forest plot (risk difference) of discontinuing because of adverse events

	Duloxetine	Duloxetine 80mg				<b>Risk Difference</b>	Risk Difference M-H, Fixed, 95% Cl		
Study or Subgroup	Events Total		Events Total		Weight	M-H, Fixed, 95% CI			
SAAW	20	140	6	138	14.5%	0.10 [0.03, 0.17]			
SBAT	51	247	12	247	25.8%	0.16 [0.10, 0.22]			
SBAV	81	344	11	339	35.7%	0.20 [0.15, 0.25]			
SBAX	38	227	4	231	23.9%	0.15 [0.10, 0.20]			
Total (95% CI)		958		955	100.0%	0.16 [0.14, 0.19]		•	
Total events	190		33						
Heterogeneity Chi <sup>2</sup> =	6.33, df = 3 (l	P = 0.10)	; I <sup>2</sup> = 539	6				abs ats	
Test for overall effect: Z = 11.59 (P < 0.00001)							-0.5 -0.25 0 Favours duloxetine 80mg	0.25 0.5 Favours placebo	

Forest plot (risk ratio) of experiencing at least one non-fatal serious adverse event



### Forest plot (risk difference) of experiencing at least one core or potential activation event

	Duloxetine 80mg		Placebo			<b>Risk Difference</b>	Risk Difference
Study or Subgroup	Events	Total	Events	<b>Events Total</b>		M-H, Fixed, 95% CI	M-H, Fixed, 95% CI
SAAW	19	140	5	138	14.5%	0.10 [0.03, 0.16]	
SBAT	47	247	10	247	25.8%	0.15 [0.10, 0.20]	
SBAV	70	344	13	339	35.7%	0.17 [0.12, 0.21]	
SBAX	51	227	14	231	23.9%	0.16 [0.10, 0.23]	
Total (95% CI)		958		955	100.0%	0.15 [0.12, 0.18]	•
Total events	187		42				
Heterogeneity. Chi2 =	2.96, df = 3 (l	P = 0.40	; I <sup>2</sup> = 0%				-0.5 -0.25 0 0.25 0.5
Test for overall effect	Z=10.52 (P	< 0.0000	01)				-0.5 -0.25 0 0.25 0.5 Favours duloxetine 80mg Favours placebo

# Forest plot (risk ratio) of experiencing at least one core or potential activation event, excluding patients who experienced solely sleep disorder or poor quality sleep

	Duloxetine 80mg		Placebo		Risk Ratio		Risk	Ratio	
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% Cl	M-H, Fixe	ed, 95% CI	
SAAW	16	140	3	138	8.9%	5.26 [1.57, 17.64]	1.0.1		
SBAT	40	247	7	247	20.6%	5.71 [2.61, 12.51]			
SBAV	68	344	13	339	38.5%	5.15 [2.90, 9.15]		<b>_</b>	
SBAX	45	227	11	231	32.1%	4.16 [2.21, 7.84]			
Total (95% CI)		958		955	100.0%	4.96 [3.47, 7.09]		•	
Total events	169		34					2000	
Heterogeneity Chi <sup>2</sup> =	0.45, df = 3 (	P = 0.93)	); $ ^2 = 0\%$				t	<u> </u>	
Test for overall effect	Z = 8.79 (P <	0.00001	)				0.02 0.1 Favours duloxetine 80mg	Favours placebo	50

	Duloxetine	80mg	Place	bo		<b>Risk Ratio</b>	Risk Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% CI	M-H, Fixed, 95% CI
SAAW	10	140	1	138	5.3%	9.86 [1.28, 75.97]	· · · · · · · · · · · · · · · · · · ·
SBAT	29	247	3	247	15.8%	9.67 [2.98, 31.32]	
SBAV	49	344	9	339	47.7%	5.37 [2.68, 10.75]	
SBAX	32	227	6	231	31.3%	5.43 [2.31, 12.73]	
Total (95% CI)		958		955	100.0%	6.30 [3.92, 10.13]	•
Total events	120		19				
Heterogeneity: Chi <sup>2</sup> =	1.02, df = 3 (f	P = 0.80)	; I² = 0%				
Test for overall effect							0.01 0.1 1 10 100 Favours duloxetine Favours placebo

Forest plot (risk ratio) of experiencing at least one event of insomnia (including initial and middle insomnia)

# Forest plot (risk difference) of experiencing at least one event of insomnia (including initial and middle insomnia)

	Duloxetine	80mg	Place	bo		<b>Risk Difference</b>	Risk Difference
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% CI	M-H, Fixed, 95% CI
SAAW	10	140	1	138	14.5%	0.06 [0.02, 0.11]	
SBAT	29	247	3	247	25.8%	0.11 [0.06, 0.15]	
SBAV	49	344	9	339	35.7%	0.12 [0.08, 0.16]	
SBAX	32	227	6	231	23.9%	0.11 [0.07, 0.16]	
Total (95% CI)		958		955	100.0%	0.11 [0.08, 0.13]	•
Total events	120		19				
Heterogeneity: Chi <sup>2</sup> =	3.63, df = 3 (l	P = 0.30)	; I <sup>2</sup> = 179	6			
Test for overall effect	Z = 9.10 (P <	0.00001	)				-0.2 -0.1 0 0.1 0.2 Favours duloxetine Favours placebo

#### Forest plot (risk ratio) of experiencing at least one core activation event

	Duloxetine	80mg	Place	bo		Risk Ratio	Risk Ratio	
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% CI	M-H, Fixed, 95% CI	
SAAW	8	140	2	138	13.4%	3.94 [0.85, 18.24]		_
SBAT	10	247	4	247	26.6%	2.50 [0.79, 7.86]		
SBAV	21	344	5	339	33.5%	4.14 [1.58, 10.85]		
SBAX	15	227	4	231	26.4%	3.82 [1.29, 11.32]		
Total (95% CI)		958		955	100.0%	3.59 [2.04, 6.32]	-	
Total events	54		15					
Heterogeneity. Chi <sup>2</sup> =	0.49, df = 3 (l	P = 0.92)	; I <sup>2</sup> = 0%					1
Test for overall effect	: Z = 4.43 (P <	0.00001	)				0.05 0.2 1 5 Favours duloxetine 80mg Favours placebo	20

	Duloxetine	80mg	Place	bo		<b>Risk Difference</b>	Risk Difference
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% CI	M-H, Fixed, 95% CI
SAAW	8	140	2	138	14.5%	0.04 [-0.00, 0.09]	
SBAT	10	247	4	247	25.8%	0.02 [-0.00, 0.05]	
SBAV	21	344	5	339	35.7%	0.05 [0.02, 0.07]	
SBAX	15	227	4	231	23.9%	0.05 [0.01, 0.09]	
Total (95% CI)		958		955	100.0%	0.04 [0.02, 0.06]	•
Total events	54		15				
Heterogeneity. Chi <sup>2</sup> =	1.56, df = 3 (l	P = 0.67)	; I <sup>2</sup> = 0%				
Test for overall effect	Z= 4.81 (P <	0.00001	)				-0.2 -0.1 0 0.1 0.2 Favours duloxetine 80mg Favours placebo

#### Forest plot (risk difference) of experiencing at least one core activation event

# Forest plot (risk ratio) of experiencing at least one FDA defined activation event

	Duloxetine	80mg	Place	bo		Risk Ratio	Risk	Ratio	
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% CI	M-H, Fixe	ed, 95% CI	
SAAW	16	140	5	138	12.9%	3.15 [1.19, 8.37]			
SBAT	40	247	9	247	23.1%	4.44 [2.20, 8.96]			
SBAV	64	344	12	339	31.0%	5.26 [2.89, 9.56]		<b>→</b>	
SBAX	48	227	13	231	33.0%	3.76 [2.09, 6.74]			
Total (95% CI)		958		955	100.0%	4.30 [3.07, 6.02]		•	
Total events	168		39					2 CO 10	
Heterogeneity. Chi2 =	= 1.03, df = 3 (F	= 0.79	); I <sup>2</sup> = 0%				0.05 0.2	ļ į	20
Test for overall effect	Z = 8.50 (P <	0.00001	)				0.05 0.2 Favours duloxetine 80mg	Favours placebo	20

Forest plot (risk ratio) of experiencing at least one FDA defined activation event, excluding patients who experienced solely sleep disorder or poor quality sleep

	Duloxetine	80mg	Place	bo		Risk Ratio	Risk	Ratio	
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% CI	M-H, Fixe	ed, 95% CI	
SAAW	13	140	3	138	9.7%	4.27 [1.24, 14.66]			
SBAT	32	247	6	247	19.3%	5.33 [2.27, 12.53]			
SBAV	61	344	12	339	39.0%	5.01 [2.75, 9.13]			
SBAX	42	227	10	231	32.0%	4.27 [2.20, 8.31]			
Total (95% CI)		958		955	100.0%	4.77 [3.27, 6.94]		•	
Total events	148		31						
Heterogeneity. Chi2 =	0.23, df = 3 (f	P = 0.97)	; I <sup>2</sup> = 0%				0.05 0.2	<u> </u>	-
Test for overall effect	Z = 8.14 (P <	0.00001	)				0.05 0.2 Favours duloxetine 80mg	Favours placebo	20

Forest plot (risk difference) of experiencing at least one event of emotional disturbance

	Duloxetine	80mg	Place	bo		<b>Risk Difference</b>	Risk Difference
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% CI	M-H, Fixed, 95% CI
SAAW	3	140	0	138	14.5%	0.02 [-0.01, 0.05]	
SBAT	5	247	0	247	25.8%	0.02 [0.00, 0.04]	
SBAV	6	344	2	339	35.7%	0.01 [-0.00, 0.03]	
SBAX	4	227	1	231	23.9%	0.01 [-0.01, 0.03]	
Total (95% CI)		958		955	100.0%	0.02 [0.01, 0.03]	◆
Total events	18		3				
Heterogeneity Chi <sup>2</sup> =	0.70, df = 3 (f	P = 0.87)	; I <sup>2</sup> = 0%				
Test for overall effect	Z = 3.15 (P =	0.002)					-0.1 -0.05 0 0.05 0.1 Favours duloxetine 80mg Favours placebo

# Forest plot (risk difference) of experiencing at least one core or potential psychotic event

	Duloxetine	80mg	Place	bo		<b>Risk Difference</b>	Risk Difference
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% CI	M-H, Fixed, 95% CI
SAAW	5	140	0	138	14.5%	0.04 [0.00, 0.07]	
SBAT	4	247	2	247	25.8%	0.01 [-0.01, 0.03]	
SBAV	7	344	5	339	35.7%	0.01 [-0.01, 0.03]	
SBAX	5	227	2	231	23.9%	0.01 [-0.01, 0.04]	
Total (95% CI)		958		955	100.0%	0.01 [0.00, 0.02]	◆
Total events	21		9				
Heterogeneity. Chi <sup>2</sup> =	2.52, df = 3 (f	= 0.47)	; I <sup>2</sup> = 0%				-0.1 -0.05 0 0.05 0.1
Test for overall effect	Z=2.17 (P=	0.03)					-0.1 -0.05 0 0.05 0.1 Favours duloxetine 80mg Favours placebo

#### Forest plot (risk ratio) of experiencing at least one core psychotic event

	Duloxetine	80mg	Place	bo		Risk Ratio	Risk Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% CI	M-H, Fixed, 95% CI
SAAW	1	140	0	138	12.5%	2.96 [0.12, 71.98]	
SBAT	2	247	1	247	24.9%	2.00 [0.18, 21.91]	
SBAV	4	344	2	339	50.2%	1.97 [0.36, 10.69]	
SBAX	2	227	0	231	12.3%	5.09 [0.25, 105.39]	
Total (95% CI)		958		955	100.0%	2.49 [0.78, 7.89]	-
Total events	9		3				
Heterogeneity. Chi <sup>2</sup> =	0.33, df = 3 (f	P = 0.95)	; I <sup>2</sup> = 0%				
Test for overall effect	Z = 1.55 (P =	0.12)					0.01 0.1 1 10 100 Favours duloxetine 80mg Favours placebo

Forest (risk ratio) of experiencing at least one core or potential depression related event

